Latest Ratios: P/E Ratio -0.0x · EV/EBITDA N/A · ROE -420.5%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $865667 | $1M | $3M | $42M | $65M | $329M | $368M | $179M | $62M | $250M | $218M |
| Enterprise Value | $-3811824 | $-3462461 | $464554 | $40M | $47M | $312M | $366M | $184M | $66M | $252M | $222M |
| P/E Ratio → | -0.04 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | 4.49 | 1.45 | 5.14 | 6.03 |
| P/B Ratio | 0.12 | 0.29 | 1.70 | 21.52 | 4.17 | 14.77 | 107.63 | 16.87 | 5.78 | 12.86 | 18.69 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | 4.60 | 1.53 | 5.19 | 6.13 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | 20.4% | 20.9% | 21.1% | 18.1% |
| Operating Margin | — | — | — | — | — | — | — | -15.8% | -16.6% | -24.6% | -14.9% |
| Net Profit Margin | — | — | — | — | — | — | — | -14.0% | -39.3% | -18.7% | -7.7% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -420.5% | -420.5% | -539.6% | -0.2% | -97.7% | -380.8% | -97.8% | -52.4% | -111.9% | -58.3% | -46.6% |
| ROA | -296.7% | -296.7% | -259.4% | -0.1% | -80.0% | -317.9% | -47.2% | -20.5% | -41.3% | -19.8% | -10.4% |
| ROIC | — | — | — | — | -990.4% | -558.9% | -49.8% | -32.0% | -29.5% | -48.5% | -40.5% |
| ROCE | -304.1% | -304.1% | -542.8% | -187.8% | -99.3% | -185.0% | -80.0% | -49.5% | -38.9% | -49.2% | -33.6% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | 0.00 | 0.01 | — | 0.46 | 0.48 | 0.37 | 0.43 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.12 | -1.41 | -1.17 | -1.14 | -0.77 | -0.46 | 0.42 | 0.36 | 0.12 | 0.31 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -82777.81 | -82777.81 | — | -4655.56 | -3801.13 | -5469.31 | -14.42 | -6.55 | -13.45 | -18.94 | -7.69 |
Net cash position: cash ($5M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.38 | 5.38 | 1.84 | 1.53 | 4.61 | 8.51 | 3.35 | 0.53 | 0.68 | 0.48 | 0.79 |
| Quick Ratio | 5.38 | 5.38 | 1.84 | 1.53 | 4.61 | 8.51 | 3.35 | 0.53 | 0.68 | 0.48 | 0.79 |
| Cash Ratio | 5.09 | 5.09 | 1.50 | 0.98 | 4.44 | 8.33 | 2.32 | 0.03 | 0.09 | 0.16 | 0.12 |
| Asset Turnover | — | — | — | — | — | — | — | 1.60 | 1.45 | 0.93 | 0.91 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | 58.38 | 66.82 | 66.39 | 81.39 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | 100.0% | 100.0% | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 40.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 40.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 100.0% | 100.0% | 0.0% |
| Shares Outstanding | — | $334719 | $41908 | $179922 | $173189 | $39362 | $9589 | $2203 | $396 | $250 | $218 |
Liquidity and dilution risk
As reported in financial statements, Enveric's P/B ratio of 0.12 suggests the market is heavily discounting the company's book value, likely due to the lack of revenue and the persistent, high-burn nature of its pre-clinical research activities compared to better-capitalized peers in the biotechnology sector.
The extremely low P/B multiple indicates that investors are assigning minimal value to the company's intellectual property library, potentially viewing it as a liability rather than an asset given the high cost of clinical validation. This valuation level suggests the market is pricing in a high probability of further equity dilution or a potential restructuring event.
Based on Enveric's reported figures, the ROE has remained consistently negative, reaching -35.4% in 2026Q1, which highlights the company's inability to generate returns on invested capital while it continues to burn through its cash reserves to fund early-stage synthetic chemistry development.
The negative ROIC and ROE trends demonstrate that the company is currently destroying shareholder value rather than compounding it. Without a transition to a revenue-generating model, these metrics will likely remain deeply negative, reflecting the structural difficulty of sustaining a research-heavy platform without commercial milestones.
According to recent SEC filings, the company's current ratio has fluctuated significantly, reaching 11.67 in 2026Q1, yet this figure is misleading as it masks the rapid depletion of cash reserves relative to the high fixed costs required to maintain the Psybrary platform.
While the current ratio appears high, it is largely a function of the company's asset-light structure and lack of significant current liabilities, rather than operational strength. Investors should monitor the cash burn rate closely, as the current liquidity position appears insufficient to support long-term clinical development without external financing.
As indicated by the peer comparison data, Enveric's valuation and profitability metrics lag behind companies like MindMed and Atai, suggesting that the market views Enveric's pre-clinical focus as structurally riskier than peers with more advanced clinical pipelines and larger cash runways.
The gap between Enveric and its peers is not merely temporary but reflects a fundamental difference in clinical stage and capital access. The company's inability to demonstrate a clear path to commercialization makes it a higher-risk outlier within the psychedelic-inspired biotechnology sector.
The current ratio is the most commonly misapplied metric for Enveric, as it obscures the company's true financial fragility by ignoring the lack of revenue and the high, non-discretionary R&D burn rate that characterizes this specific pre-commercial biotechnology business model.
Using standard liquidity ratios to assess a pre-revenue firm provides a false sense of security, as these metrics do not account for the binary nature of clinical trial funding. A more appropriate metric would be the 'Cash Runway Ratio,' which measures the months of survival remaining based on current burn, rather than the static relationship between current assets and liabilities.
Includes 30+ ratios · 30 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ENVB stock.
Enveric Biosciences, Inc.'s current P/E ratio is -0.0x. The historical average is 10.4x.
Enveric Biosciences, Inc.'s return on equity (ROE) is -420.5%. The historical average is -84.5%.
Based on historical data, Enveric Biosciences, Inc. is trading at a P/E of -0.0x. Compare with industry peers and growth rates for a complete picture.